Our finding that trial-eligible and ineligible ASCVD patients had comparable outcomes aligns with previous studies on the applicability of sodium-glucose cotransporter 2 inhibitor trials and trials on antithrombotic treatment intensification in ASCVD populations.33,34 In contrast, in heart failure with reduced ejection fraction (HFrEF), ineligible patients have been shown to have worse outcomes than eligible ones.35,36 This discrepancy likely reflects differences in trial design. The gene discussed is SLC5A2; the disease is heart failure.